Quantitative evaluation of policies for the commercialization of traditional Chinese medicine preparations in medical institutions into new drugs in China

GAO Qian; CHEN Ning; HE Zhaonan; FAN Jie; ZHANG Yuxin; CHEN Jingjia; LIU Wei

doi:10.6039/j.issn.1001-0408.2026.20.04

您当前的位置：

首页 >

文章列表页 >

Quantitative evaluation of policies for the commercialization of traditional Chinese medicine preparations in medical institutions into new drugs in China

更新时间：2026-10-29

- Quantitative evaluation of policies for the commercialization of traditional Chinese medicine preparations in medical institutions into new drugs in China
- ZHONGGUO YAOFANG Vol. 37, Issue 20, Pages: 2647-2653(2026)
- 作者机构：
  
  1.北京中医药大学管理学院，北京;100029
  2.北京中医药大学大学科技园管理办公室/技术转移转化中心，北京　100029
  3.中国康复研究中心（北京博爱医院）科研处，北京　100068
  4.首都医科大学附属北京中医医院科研处，北京　100010
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.20.04
  CLC： R95
- Received：06 July 2026，
  
  Revised：2026-10-19，
  
  Accepted：19 October 2026，
  
  Published：30 October 2026
- 稿件说明：
移动端阅览
高茜,陈宁,何照楠,等.我国医疗机构中药制剂新药转化政策的量化评价 [J].中国药房,2026,37(20):2647-2653.

GAO Qian,CHEN Ning,HE Zhaonan,et al.Quantitative evaluation of policies for the commercialization of traditional Chinese medicine preparations in medical institutions into new drugs in China[J].ZHONGGUO YAOFANG,2026,37(20):2647-2653.
高茜,陈宁,何照楠,等.我国医疗机构中药制剂新药转化政策的量化评价 [J].中国药房,2026,37(20):2647-2653. DOI： 10.6039/j.issn.1001-0408.2026.20.04.

GAO Qian,CHEN Ning,HE Zhaonan,et al.Quantitative evaluation of policies for the commercialization of traditional Chinese medicine preparations in medical institutions into new drugs in China[J].ZHONGGUO YAOFANG,2026,37(20):2647-2653. DOI： 10.6039/j.issn.1001-0408.2026.20.04.

摘要

目的

对国内医疗机构中药制剂新药转化政策进行量化评价，为完善和优化我国医疗机构中药制剂新药转化政策体系提供参考。

方法

检索北大法宝数据库及相关部门官方网站，收集和筛选相关政策文件，运用ROST-CM 6.0软件对政策文本进行文本挖掘，结合政策工具分析及相关文献构建PMC评价指标体系，通过二元赋值计算PMC指数并划分评价等级，利用MATLAB R2024a软件绘制PMC曲面图，以揭示政策体系的结构特征与薄弱环节，并提出优化建议。结果与

结论

共纳入44份医疗机构中药制剂新药转化相关政策，构建出包含10个一级变量、44个二级变量的PMC指数模型。44份政策的PMC指数均值为6.07，评价等级为可接受水平。一级变量中，“政策性质”“政策方式”“政策评价”得分较高，“政策工具”“政策对象”等得分较低，主要表现为资金、人才及知识产权转化支持措施不够充分，政策对象覆盖有待拓展，转化支持系统性相对不足。建议相关部门在出台政策时，可强化资金、人才、知识产权支撑，增强地方特色适配性，扩大主体覆盖范围，制定专项支持政策，以推动更多临床价值高、特色优势明显的医疗机构中药制剂转化为新药。

Abstract

OBJECTIVE

To quantitatively evaluate the policies for the commercialization of traditional Chinese medicine preparations in medical institutions into new drugs， and to provide a reference for improving and optimizing China’s policy system for the commercialization of such preparations into new drugs.

METHODS

Relevant policy documents were retrieved from the PKULaw database and official websites of relevant departments. After collection and screening， the policy texts were text-mined with ROST-CM 6.0 software. A policy modeling consistency （PMC） evaluation index system was constructed by combining the analysis of policy instruments with relevant literature. The PMC indices were calculated through binary assignment， and the evaluation grades were classified. MATLAB R2024a software was used to draw PMC surface maps， so as to reveal the structural characteristics and weak links of the policy system and put forward optimization suggestions.

RESULTS &CONCLUSIONS

A total of 44 policies related to the commercialization of traditional Chinese medicine preparations in medical institutions into new drugs were included， and a PMC index model containing 10 first-level variables and 44 second-level variables was constructed. The mean PMC index of the 44 policies was 6.07， and the overall evaluation grade was acceptable. Among the first-level variables， “policy nature”“policy approach”“policy evaluation” scored relatively high， whereas “policy instruments”“policy targets” scored relatively low. These findings were mainly reflected in insufficient support measures for funding， professionals and intellectual property rights transformation， limited coverage of policy targets， and relatively inadequate systematic support for commercialization. It is recommended that relevant departments strengthen financial， talent and intellectual property support， enhance local adaptability， expand the coverage of target entities， and formulate special support policies， so as to promote the commercialization of more traditional Chinese medicine preparations with high clinical value and distinctive advantages into new drugs.

关键词

Keywords

references

国家药品监督管理局 . 国家药监局关于促进中药传承创新发展的实施意见 [EB/OL ] .（ 2020-12-21 ）[ 2026-10-14 ] . https：//www.gov.cn/zhengce/zhengceku/2020-12/26/content_5573463.htm https://www.gov.cn/zhengce/zhengceku/2020-12/26/content_5573463.htm .

麦嘉曦 . 医疗机构中药制剂成果转化的现状及难点 [J ] . 质量与市场， 2023 （ 18 ）： 250 - 252 .

叶心怡，罗李娜 . 医疗机构中药制剂转化关键问题思考 [J ] . 中国新药杂志， 2025 ， 34 （ 2 ）： 143 - 146 .

Rothwell R ， Zegveld W . An assessment of government innovation policies [J ] . Rev Policy Res ， 1984 ， 3 （ 3/4 ）： 436 - 444 .

Ruiz Estrada M A . Policy modeling：definition，classification and evaluation [J ] . J Policy Model ， 2011 ， 33 （ 4 ）： 523 - 536 .

何照楠，纪雨菲，卢守四，等 . 基于PMC指数模型的我国康复领域科技创新政策评价研究 [J ] . 中国卫生事业管理， 2025 ， 42 （ 6 ）： 606 - 611，691 .

罗金萍，孙嘉颖，牟艺帆，等 . 我国儿童用药政策的量化评价：基于政策建模一致性指数模型 [J ] . 中国全科医学， 2025 ， 28 （ 21 ）： 2652 - 2660 .

孙远太，周俍琛 . 政策工具视角下我国按病种分值付费改革政策文本量化评价研究 [J ] . 中国医疗管理科学， 2025 ， 15 （ 3 ）： 1 - 9 .

刘小雅，邵明义，符宇，等 . 中药院内制剂开发的问题与策略 [J ] . 世界科学技术-中医药现代化， 2023 ， 25 （ 5 ）： 1782 - 1787 .

汤子健，黎犇，李青，等 . 我国医保基金监管政策的量化评价：基于PMC指数模型分析 [J ] . 中国卫生事业管理， 2025 ， 42 （ 5 ）： 531 - 537 .

马忠明，欧阳辉，倪健，等 . 医疗机构中药制剂现状及其对中药新药研发路径的启发 [J ] . 中国中药杂志， 2024 ， 49 （ 5 ）： 1415 - 1420 .

李培，陈玉文 . 真实世界证据支持医疗机构中药制剂转化为新药的思考 [J ] . 中国新药杂志， 2022 ， 31 （ 24 ）： 2475 - 2480 .

纪国涛，王佳杰 . 我国高校科技成果转化政策量化评价研究：以辽宁省10所高校的PMC指数模型分析为例 [J ] . 中国高校科技， 2022 （ 11 ）： 22 - 27 .

齐琪，许保海，陆洋 . 基于医疗机构中药制剂研发策略与新药转化的思考 [J ] . 中国药事， 2021 ， 35 （ 12 ）： 1357 - 1363 .

刘莉，张磊，元唯安，等 . 源自医疗机构中医临床实践中药新药创制评价指标体系构建的专家共识 [J ] . 中国中药杂志， 2025 ， 50 （ 12 ）： 3474 - 3482 .

罗金萍，孙嘉颖，耿铭慧，等 . 基于政策建模一致性指数模型的我国惠民保政策量化评价 [J ] . 现代预防医学， 2025 ， 52 （ 9 ）： 1636 - 1641，1693 .

翟运开，郭柳妍，赵栋祥，等 . 基于PMC指数模型的远程医疗政策评价 [J ] . 信息资源管理学报， 2022 ， 12 （ 2 ）： 112 - 122，137 .

浙江省卫生健康委员会 . 浙江省卫生健康委关于省政协十三届四次会议第677号提案的答复 [EB/OL ] .（ 2026-06-02 ）[ 2026-16-14 ] . https：//wsjkw.zj.gov.cn/col/col- 1229129056/art/2026/art_a7a0022c19c541ceb69701096c-1657da.html https://wsjkw.zj.gov.cn/col/col-1229129056/art/2026/art_a7a0022c19c541ceb69701096c-1657da.html .

广东省药品监督管理局 . 【南方日报】广东省药监局破题中药创新 “岭南名方”从院内制剂走向市场 [EB/OL ] .（ 2026-04-28 ）[ 2026-06-14 ] . https：//mpa.gd.gov.cn/xwdt/xwfbpt/mtzx/content/post_4890376.html https://mpa.gd.gov.cn/xwdt/xwfbpt/mtzx/content/post_4890376.html .

广东省药品监督管理局 .【中国医药报】走在前列的广东药监｜激活院内制剂促进新药转化：“岭南名方”遴选助力中药传承创新 [EB/OL ] .（ 2025-12-17 ）[ 2026-04-28 ] . https：//mpa.gd.gov.cn/xwdt/xwfbpt/mtzx/content/post_4830551.html https://mpa.gd.gov.cn/xwdt/xwfbpt/mtzx/content/post_4830551.html .

林卡娜，沈安乐，王业健，等 . 产学研协同创新理论视角下医疗机构制剂平台建设新模式探索 [J ] . 中国药房， 2026 ， 37 （ 2 ）： 137 - 141 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Quantitative evaluation and countermeasure suggestions on support policies for the development of traditional Chinese medicine preparations in medical institutions in China

Quantitative evaluation for payment policy of diagnosis-related groups in China based on PMC index model

Policy analysis of high-quality development of traditional Chinese medicine based on PMC index model

Quantitative Evaluation of Chronic Disease Management Policy in China Based on PMC Index Model

Construction of hospital preparation cost item library based on the Delphi method

Related Author

WU Qingyan

YU Wenxue

LI Jia

WU Shanying

WU Fang

HOU Yanhong

FU Manxia

WU Tingting

Related Institution

School of Medical Business， Guangdong Pharmaceutical University

Guangdong Health Economics and Health Promotion Research Center

⁰